About Seer, Inc
Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration program agreement with Discovery Life Sciences, LLC; and commercial agreements with Bruker Scientific LLC and Thermo Electron North America LLC. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California. Address: 3800 Bridge Parkway, Redwood City, CA, United States, 94065
Seer, Inc News and around…
Latest news about Seer, Inc (SEER) common stock and company :
As every investor would know, you don't hit a homerun every time you swing. But it would be foolish to simply accept...
Earlier today, Seer released financial results for the quarter ending March 31, 2022. Joining me today from Seer is Omid Farokhzad, chairman, chief executive officer and founder; Omead Ostadan, president; and David Horn, chief financial officer.
Seer, Inc. (SEER) delivered earnings and revenue surprises of 7.32% and 18.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Demonstrated solid commercial traction with continued robust interest in the Proteograph Product SuiteREDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the first quarter ended March 31, 2022. “We had a strong start to the year as we further ramped our commercial efforts, expanded our installed base, and made tangible progress against our strategic
REDWOOD CITY, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada. Seer’s management is scheduled to participate in a fireside chat on Tuesday, May 10 at 4:40 p.m. Pacific Time / 7:40 p.m. Eastern Time. A live webcast of the virtual session will be available on the
Seer, Inc. (SEER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the first quarter of 2022 on Wednesday, May 4, 2022. Company management will be webcasting a conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An
Seasoned life sciences executive adds extensive global sales expertise to drive commercial effortsREDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, announced today the appointment of Scott D. Thomas as Chief Commercial Officer effective March 21, 2022. Mr. Thomas joins Seer from Singular Genomics, where he served as Senior Vice President, Sales and Marketing. Prior to Singular, he
Published results highlight simultaneous superior performance across depth, precision, and throughput versus conventional plasma proteomics workflows REDWOOD CITY, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) today announced the publication of a study demonstrating the performance of the technology platform underlying the Proteograph Product Suite™ for deep, unbiased, precise, scalable proteomics. The paper, entitled “Engineered Nanoparticles Enable Deep Proteomics Studie
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
The tale of how Omid Farokhzad came to the United States from his native Iran has many twists, but he is writing a much less-complicated story with Seer Inc.: The five-year-old company is helping researchers look deeper into proteins more accurately at a faster pace to find treatments for a broad range of diseases. Farokhzad had already started four companies and was a professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital in Boston when he started Seer, but said if the company is successful, it could help launch a new wave of protein research, called proteomics. When we met four years ago or so, you said Seer could do for proteomics what Illumina did for genomics.
Earlier today, Seer released financial results for the quarter and year ending December 31, 2021. Joining me today from Seer is Omid Farokhzad, chairman, chief executive officer, and founder; and David Horn, chief financial officer.
Demonstrated tangible market progress and shipped 17 instruments through year end 2021REDWOOD CITY, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today reported financial results for the fourth quarter and full year ended December 31, 2021. “This has been a momentous year for Seer, one that paved the way for our technology in the hands of lighthouse collaborators and customers, demonstrated t
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating virtually in the upcoming Cowen 42nd Annual Health Care Conference. Seer’s management is scheduled to participate in a fireside chat on Tuesday, March 8 at 11:50 a.m. Pacific Time / 2:50 p.m. Eastern Time. A live webcast of the virtual session will be available on the Investor se
Seer, Inc. (SEER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Monday, February 28, 2022. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s
Company has already booked multiple orders and established COEs in three major geographies Seer’s Proteograph Product Suite Announcing Broad Commercial Release REDWOOD CITY, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced Broad Commercial Release of its Proteograph Product Suite and the launch of its Centers of Excellence program. The Proteograph Product Suite provides unpreceden
Delivery of 100,000 samples of capacity annually to the market, empowering genomics researchers to add deep, unbiased proteomics analysis to their studies Proteogenomics Consortium Bringing deep, unbiased proteomic to genomics customers REDWOOD CITY, Calif. and HUNTSVILLE, Ala. and FRAMINGHAM, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics; SCIEX, a global leader in life science analytical techno
Company has already booked multiple orders and established COEs in three major geographies Seer’s Proteograph Product Suite Announcing Broad Commercial Release REDWOOD CITY, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced Broad Commercial Release of its Proteograph Product Suite and the launch of its Centers of Excellence program. The Proteograph Product Suite provides unpreceden
LOS ANGELES, CA / ACCESSWIRE / December 31, 2021 /The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. ("Seer" or "the Company") (NASDAQ:SEER) for violations of the securities laws.
Seer, Inc (SEER) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
